The increasing utilization of biological medicines, combined with their high costs, imposes a significant financial burden on healthcare systems worldwide. Biosimilars offer a cost-effective alternative without compromising quality, efficacy, or safety, but their development is hindered by varying regulatory requirements across jurisdictions. Advancements in analytical sciences, along with accumulated knowledge from regulatory approval and clinical practice, present an opportunity for science-driven regulatory convergence.

Towards Regulatory Convergence for Biosimilars: Recommendations from an International Qualitative study

Collaborating for Healthcare Innovation – a focus on Sustainability!

18-20 March 2025
Basel, Switzerland

DIA Europe 2025 will focus on sustainability, innovation and collaboration – three key pillars for shaping the future of healthcare. From the environmental impact of pharmaceuticals and of the drug development lifecycle to sustainable partnerships and sustainable healthcare systems, DIA Europe 2025 will be the prime opportunity to discuss how collaboration and innovation can support sustainability in healthcare and each stakeholder’s role in making it happen.

Join us in the vibrant city of Basel for an unforgettable experience, where the power of collaboration will be on full display to inspire actionable outcomes and mobilise for solutions the life sciences’ community. Witness first-hand the profound impact of united efforts, gain valuable insights from across the drug development lifecycle, and play an active role in shaping the future of the pharmaceutical arena.

DIA Europe 2025

A global, member-driven non-profit organization mobilizing life sciences and healthcare. DIA fosters innovation to improve health and well-being worldwide. Professionals from 80 countries continue to engage with DIA through our unparalleled membership network, educational offerings, and professional development opportunities.